Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.

Quintela-Fandino M, Apala JV, Malon D, Mouron S, Hornedo J, Gonzalez-Cortijo L, Colomer R, Guerra J.

Breast Cancer Res. 2019 May 24;21(1):69. doi: 10.1186/s13058-019-1152-x.

2.

A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer.

Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, Alcindor T, Colomer R.

Pancreas. 2019 May/Jun;48(5):e45-e47. doi: 10.1097/MPA.0000000000001294. No abstract available.

PMID:
31090669
3.

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A.

Oncologist. 2019 May;24(5):603-611. doi: 10.1634/theoncologist.2018-0228. Epub 2019 Feb 1.

PMID:
30710068
4.

Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.

Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.

Eur J Cancer. 2019 Mar;109:21-27. doi: 10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22.

PMID:
30682533
5.

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.

Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M.

Nat Commun. 2018 Aug 29;9(1):3501. doi: 10.1038/s41467-018-05742-z.

6.

Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.

Gómez-León N, Pacheco-Barcia V, Ballesteros AI, Fraga J, Colomer R, Friera A.

Melanoma Res. 2018 Dec;28(6):562-570. doi: 10.1097/CMR.0000000000000466.

7.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Aug;20(8):1093-1095. doi: 10.1007/s12094-018-1909-1.

PMID:
29916189
8.

Nivolumab-induced thyroid dysfunction in patients with lung cancer.

Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M.

Endocrinol Diabetes Nutr. 2019 Jan;66(1):26-34. doi: 10.1016/j.endinu.2018.05.005. Epub 2018 Jun 15. English, Spanish.

PMID:
29910159
9.

[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R.

Rev Esp Patol. 2018 Apr - Jun;51(2):97-109. doi: 10.1016/j.patol.2017.12.002. Epub 2018 Mar 14. Spanish.

PMID:
29602380
10.

Predictors of unknown cancer in patients with ischemic stroke.

Quintas S, Rogado J, Gullón P, Pacheco-Barcia V, Dotor García-Soto J, Reig-Roselló G, Mondéjar R, Colomer R, Vivancos J.

J Neurooncol. 2018 May;137(3):551-557. doi: 10.1007/s11060-017-2741-0. Epub 2018 Jan 8.

PMID:
29313183
11.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5. Epub 2017 Dec 22. Review. Erratum in: Clin Transl Oncol. 2018 Jun 18;:.

12.

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773.

13.

Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.

Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY.

Breast Cancer Res Treat. 2018 Feb;168(1):197-205. doi: 10.1007/s10549-017-4567-z. Epub 2017 Nov 23.

14.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

15.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

16.

Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.

Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, Colomer R, Benhamú B, López-Rodríguez ML, Valent P, Grunt TW.

Oncotarget. 2017 Feb 14;8(7):11600-11613. doi: 10.18632/oncotarget.14591.

17.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R.

Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.

18.

Advanced breast cancer clinical nursing curriculum: review and recommendations.

Vila C, Reñones C, Ferro T, Peñuelas MÁ, Del Mar Jiménez M, Rodríguez-Lescure Á, Muñoz M, Colomer R.

Clin Transl Oncol. 2017 Feb;19(2):251-260. doi: 10.1007/s12094-016-1530-0. Epub 2016 Aug 3. Review.

19.

Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?

Colomer R, Pascual T, Albanell J.

J Clin Oncol. 2016 Sep 10;34(26):3226-7. doi: 10.1200/JCO.2016.68.2534. Epub 2016 Jul 18. No abstract available.

PMID:
27432928
20.

Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors.

Bueno MJ, Sanchez J, Colomer R, Quintela-Fandino M.

Curr Drug Targets. 2016;17(15):1735-1746. Review.

PMID:
27138758
21.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA.

JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.

PMID:
27078022
22.

Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy.

Collazo Lorduy A, Obispo B, Villar K, Buchser D, Rogado J, de la Maza MD, Alfranca YL, Colomer R.

Rare Tumors. 2015 Dec 29;7(4):5981. doi: 10.4081/rt.2015.5981. eCollection 2015 Dec 29.

23.

Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.

Colomer R, Sarrats A, Lupu R, Puig T.

Curr Drug Targets. 2017;18(2):147-159. doi: 10.2174/1389450117666160112113930. Review.

PMID:
26758667
24.

A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms.

Bueno MJ, Colomer R.

EBioMedicine. 2015 Aug;2(8):778-779. doi: 10.1016/j.ebiom.2015.08.023. Epub 2015 Aug 14. No abstract available.

25.

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.

Martin-Castillo B, Lopez-Bonet E, Buxó M, Dorca J, Tuca-Rodríguez F, Ruano MA, Colomer R, Menendez JA.

Oncotarget. 2015 Mar 30;6(9):7104-22.

26.

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.

Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW.

Int J Cancer. 2015 May 1;136(9):2078-90. doi: 10.1002/ijc.29261. Epub 2014 Nov 3.

27.

Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.

Quintela-Fandino M, Bueno MJ, Lombardia L, Gil M, Gonzalez-Martin A, Marquez R, Bratos R, Guerra J, Tan E, Lopez A, Colomer R, Salazar R.

Mol Oncol. 2014 Dec;8(8):1719-28. doi: 10.1016/j.molonc.2014.07.005. Epub 2014 Jul 17.

28.

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, Hernandez-Agudo E, Rodriguez-Martin C, Gil-Martin M, Bratos R, Escudero MJ, Vlassak S, Hilberg F, Colomer R.

Br J Cancer. 2014 Sep 9;111(6):1060-4. doi: 10.1038/bjc.2014.397. Epub 2014 Jul 24.

29.

Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.

Gascón P, Rodríguez CA, Valentín V, Mata JG, Carulla J, Cassinello J, Colomer R, Baró E.

Support Care Cancer. 2013 Nov;21(11):3039-49. doi: 10.1007/s00520-013-1862-z. Epub 2013 Jun 22.

30.

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.

Quintela-Fandino M, Krzyzanowska M, Duncan G, Young A, Moore MJ, Chen EX, Stathis A, Colomer R, Petronis J, Grewal M, Webster S, Wang L, Siu LL.

Br J Cancer. 2013 Apr 2;108(6):1298-305. doi: 10.1038/bjc.2013.64. Epub 2013 Feb 14.

31.

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I, Provencio M, González-Martín A, Pérez M.

Clin Transl Oncol. 2013 Jun;15(6):477-83. doi: 10.1007/s12094-012-0953-5. Epub 2012 Dec 19.

32.

New synthetic inhibitors of fatty acid synthase with anticancer activity.

Turrado C, Puig T, García-Cárceles J, Artola M, Benhamú B, Ortega-Gutiérrez S, Relat J, Oliveras G, Blancafort A, Haro D, Marrero PF, Colomer R, López-Rodríguez ML.

J Med Chem. 2012 Jun 14;55(11):5013-23. doi: 10.1021/jm2016045. Epub 2012 May 16.

PMID:
22559865
33.

A new multidisciplinary Spanish Working Group on Cancer Biomarkers: presentation and aims.

Colomer R, Garrido P, de Álava E, García Alfonso P, Palacios J, Ariza A; Multidisciplinary Working Group on Cancer Biomarkers of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Clin Transl Oncol. 2012 May;14(5):323-4. No abstract available.

PMID:
22551536
34.

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.

Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R.

Breast Cancer Res. 2011;13(6):R131. doi: 10.1186/bcr3077. Epub 2011 Dec 16.

35.

Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.

Gómez-Martín C, Concha A, Corominas JM, García-Caballero T, García-García E, Iglesias M, López JA, Ramón y Cajal S, Rojo F, Palacios J, Vera-Sempere F, Aranda E, Colomer R, García-Alfonso P, Garrido P, Rivera F, López-Ríos F; Spanish Society of Medical Oncology; Spanish Society of Pathology.

Clin Transl Oncol. 2011 Sep;13(9):636-51.

PMID:
21865135
36.

Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.

Quintela-Fandino M, Colomer R.

J Clin Oncol. 2011 Sep 20;29(27):3716-8; author reply 3718-9. doi: 10.1200/JCO.2011.37.1427. Epub 2011 Aug 22. No abstract available.

PMID:
21860002
37.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

Ann Oncol. 2012 Mar;23(3):625-31. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6.

PMID:
21652577
38.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.

Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A.

Clin Transl Oncol. 2011 Mar;13(3):179-84. doi: 10.1007/s12094-011-0637-6.

PMID:
21421462
39.

A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.

Castro J, Ribó M, Puig T, Colomer R, Vilanova M, Benito A.

Invest New Drugs. 2012 Jun;30(3):880-8. doi: 10.1007/s10637-011-9636-2. Epub 2011 Feb 1.

PMID:
21286781
40.

3D Assessment of Lymph Nodes vs. RECIST 1.1.

Steger S, Franco F, Sverzellati N, Chiari G, Colomer R.

Acad Radiol. 2011 Mar;18(3):391-4. doi: 10.1016/j.acra.2010.11.010. Epub 2011 Jan 7.

PMID:
21216161
41.

Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.

Oliveras G, Blancafort A, Urruticoechea A, Campuzano O, Gómez-Cabello D, Brugada R, López-Rodríguez ML, Colomer R, Puig T.

Ann N Y Acad Sci. 2010 Oct;1210:86-92. doi: 10.1111/j.1749-6632.2010.05777.x.

PMID:
20973802
42.

Targeting cytoskeleton reorganisation as antimetastatic treatment.

Quintela-Fandino M, González-Martín A, Colomer R.

Clin Transl Oncol. 2010 Oct;12(10):662-9. doi: 10.1007/s12094-010-0575-8. Review.

PMID:
20947480
43.

Antimicrobial cyclic decapeptides with anticancer activity.

Feliu L, Oliveras G, Cirac AD, Besalú E, Rosés C, Colomer R, Bardají E, Planas M, Puig T.

Peptides. 2010 Nov;31(11):2017-26. doi: 10.1016/j.peptides.2010.07.027. Epub 2010 Aug 11.

PMID:
20708052
44.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R.

Eur Respir J. 2011 Mar;37(3):624-31. doi: 10.1183/09031936.00195609. Epub 2010 Jul 1.

45.

Current controversies in the management of breast cancer.

Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):278-86. Review. Erratum in: Clin Transl Oncol. 2010 Aug;12(8):581. Muñoz, M [added].

PMID:
20462837
46.

Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer.

Baró E, Carulla J, Cassinello J, Colomer R, Mata JG, Gascón P, Gasquet JA, Rodríguez CA, Valentín V.

Support Care Cancer. 2011 May;19(5):657-66. doi: 10.1007/s00520-010-0878-x. Epub 2010 Apr 30.

47.

[Complications of intramuscular metastasis in a patient with lung cancer].

Porta R, Remollo S, Izquierdo A, Colomer R.

Med Clin (Barc). 2011 Mar 12;136(6):273-4. doi: 10.1016/j.medcli.2010.02.020. Epub 2010 Apr 22. Spanish. No abstract available.

PMID:
20416908
48.

Selection of extreme phenotypes: the role of clinical observation in translational research.

Pérez-Gracia JL, Gúrpide A, Ruiz-Ilundain MG, Alfaro Alegría C, Colomer R, García-Foncillas J, Melero Bermejo I.

Clin Transl Oncol. 2010 Mar;12(3):174-80. Review.

49.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology.

Ann Oncol. 2010 Feb;21(2):195-8. doi: 10.1093/annonc/mdp595. No abstract available.

50.

Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.

Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortés J.

J Clin Oncol. 2010 Feb 20;28(6):960-6. doi: 10.1200/JCO.2009.23.1910. Epub 2009 Dec 21.

PMID:
20026806

Supplemental Content

Loading ...
Support Center